142.44

0.84% 1.19

Neurocrine Biosciences Inc (NBIX)

Overview News Price History Option Chain Financials Discussions Forecast

Neurocrine Biosciences Inc stock is traded at $142.44, with a volume of 1.02M. It is up +0.84% in the last 24 hours and down -8.19% over the past month. Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Previous Close:

$141.25

Open:

$141.33

24h Volume:

1.02M

Relative Volume:

0.68

Market Cap:

$14.48B

Revenue:

$3.10B

Net Income/Loss:

$668.60M

P/E Ratio:

21.90

EPS:

6.5044

Net Cash Flow:

$831.30M

1W Performance:

-0.52%

1M Performance:

-8.19%

6M Performance:

+8.20%

1Y Performance:

+2.87%

1-Day Range:

$140.02

$143.55

1-Week Range:

$140.02

$146.91

52-Week Range:

$122.14

$186.12

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name

Neurocrine Biosciences Inc

Sector

Healthcare (1050)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(858) 617-7600

Address

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Employee

2,000

Twitter

Next Earnings Date

2026-10-27

Latest SEC Filings

NBIX's Discussions on Twitter

Compare NBIX vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBIX Neurocrine Biosciences Inc	142.44	14.48B	3.10B	668.60M	831.30M	6.5044
TAK Takeda Pharmaceutical Co Adr	18.73	59.83B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.10	47.93B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.32	40.99B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	74.81	30.91B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.16	23.55B	3.17B	1.29B	1.01B	27.09

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-06-26	Resumed	Guggenheim	Buy
Jun-02-26	Resumed	Goldman	Buy
May-22-26	Initiated	Bernstein	Outperform
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-21-25	Initiated	Citigroup	Buy
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Initiated	Goldman	Buy
Apr-15-25	Upgrade	Needham	Hold → Buy
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-11-25	Initiated	Deutsche Bank	Hold
Oct-10-24	Resumed	Raymond James	Outperform
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Resumed	Citigroup	Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-21-23	Reiterated	Mizuho	Neutral
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-04-23	Upgrade	Guggenheim	Neutral → Buy
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-22	Initiated	UBS	Buy
Sep-26-22	Initiated	Wells Fargo	Equal Weight
Jun-06-22	Resumed	Jefferies	Buy
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral
Feb-25-22	Upgrade	Goldman	Neutral → Buy
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-19-21	Initiated	BMO Capital Markets	Underperform
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Aug-06-21	Downgrade	Canaccord Genuity	Buy → Hold
May-18-21	Resumed	Goldman	Neutral
May-06-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-02-21	Initiated	Raymond James	Outperform
Sep-30-20	Initiated	The Benchmark Company	Hold
Aug-04-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-29-20	Downgrade	Goldman	Buy → Neutral
Jun-09-20	Initiated	Wedbush	Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-24-20	Initiated	William Blair	Outperform
Feb-06-20	Initiated	Mizuho	Neutral
Feb-05-20	Reiterated	H.C. Wainwright	Buy
Dec-13-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-07-19	Initiated	RBC Capital Mkts	Outperform
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-05-19	Initiated	Guggenheim	Neutral
May-21-19	Initiated	Credit Suisse	Outperform
Apr-22-19	Upgrade	JP Morgan	Neutral → Overweight
Apr-12-19	Initiated	Evercore ISI	Outperform
Feb-06-19	Reiterated	BofA/Merrill	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-13-18	Initiated	Goldman	Buy
Nov-21-18	Initiated	Canaccord Genuity	Buy

View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

Oct 09, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research

Oct 09, 2026

Oct 07, 2026

A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. - Stock Titan

Oct 07, 2026

Neurocrine Biosciences (NBIX) After New VYKAT XR Data Why The Undervalued Narrative Persists - Simply Wall Street

Oct 07, 2026

Neurocrine Biosciences stock fell 1.4 percent before research event - AD HOC NEWS

Oct 07, 2026

Oct 05, 2026

Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock - ChartMill

Oct 05, 2026

Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high - AD HOC NEWS

Oct 05, 2026

Oct 03, 2026

Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst - Moomoo

Oct 03, 2026

Oct 02, 2026

Moderna, Neurocrine bring back familiar faces; Pharming CEO exits after clashing with board - Endpoints News

Oct 02, 2026

Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation - ChartMill

Oct 02, 2026

Oct 01, 2026